Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

Noopur S. Raje, Philippe Moreau, Evangelos Terpos, Lotfi Benboubker, Norbert Grząśko, Sarah A Holstein, Albert Oriol, Shang Yi Huang, Meral Beksac, Kazimierz Kuliczkowski, Datchen F. Tai, James E. Wooldridge, Ilaria Conti, Christopher J. Kaiser, Tuan S. Nguyen, Damien M. Cronier, Antonio Palumbo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N�=�72), tabalumab 100�mg (N�=�74), or tabalumab 300�mg (N�=�74), each in combination with dexamethasone 20�mg and subcutaneous bortezomib 1�3�mg/m2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6�6, 7�5 and 7�6�months for the tabalumab 100, 300�mg and placebo groups, respectively (tabalumab 100�mg vs. placebo Hazard ratio (HR) [95% confidence interval (CI)]�=�1�13 [0�80–1�59], P�=�0�480; tabalumab 300�mg vs. placebo HR [95% CI]�=�1�03 [0�72–1�45], P�=�0�884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n�=�162) had significantly longer mPFS than those with high BAFF expression (n�=�55), using the 75th percentile cut-off point (mPFS [95% CI]�=�8�3 [7�0–9�3] months vs. 5�8 [3�7–6�6] months; HR [95% CI]�=�1�59 [1�11–2�29], P�=�0�015). Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo. A higher dose of 300�mg tabalumab did not improve efficacy compared to the 100�mg dose. Nonetheless, BAFF appears to have some prognostic value in patients with multiple myeloma.

Original languageEnglish (US)
Pages (from-to)783-795
Number of pages13
JournalBritish Journal of Haematology
Volume176
Issue number5
DOIs
StatePublished - Mar 1 2017

Fingerprint

B-Cell Activating Factor
Multiple Myeloma
Dexamethasone
Antibodies
Placebos
Disease-Free Survival
Confidence Intervals
Constipation
Bortezomib
tabalumab
Thrombocytopenia
Fatigue
Diarrhea
Therapeutics

Keywords

  • B-cell activating factor (BAFF)
  • bortezomib
  • multiple myeloma
  • tabalumab
  • treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. / Raje, Noopur S.; Moreau, Philippe; Terpos, Evangelos; Benboubker, Lotfi; Grząśko, Norbert; Holstein, Sarah A; Oriol, Albert; Huang, Shang Yi; Beksac, Meral; Kuliczkowski, Kazimierz; Tai, Datchen F.; Wooldridge, James E.; Conti, Ilaria; Kaiser, Christopher J.; Nguyen, Tuan S.; Cronier, Damien M.; Palumbo, Antonio.

In: British Journal of Haematology, Vol. 176, No. 5, 01.03.2017, p. 783-795.

Research output: Contribution to journalArticle

Raje, NS, Moreau, P, Terpos, E, Benboubker, L, Grząśko, N, Holstein, SA, Oriol, A, Huang, SY, Beksac, M, Kuliczkowski, K, Tai, DF, Wooldridge, JE, Conti, I, Kaiser, CJ, Nguyen, TS, Cronier, DM & Palumbo, A 2017, 'Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma', British Journal of Haematology, vol. 176, no. 5, pp. 783-795. https://doi.org/10.1111/bjh.14483
Raje, Noopur S. ; Moreau, Philippe ; Terpos, Evangelos ; Benboubker, Lotfi ; Grząśko, Norbert ; Holstein, Sarah A ; Oriol, Albert ; Huang, Shang Yi ; Beksac, Meral ; Kuliczkowski, Kazimierz ; Tai, Datchen F. ; Wooldridge, James E. ; Conti, Ilaria ; Kaiser, Christopher J. ; Nguyen, Tuan S. ; Cronier, Damien M. ; Palumbo, Antonio. / Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. In: British Journal of Haematology. 2017 ; Vol. 176, No. 5. pp. 783-795.
@article{87d3e522e63148179aff34d25f0463cf,
title = "Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma",
abstract = "In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N�=�72), tabalumab 100�mg (N�=�74), or tabalumab 300�mg (N�=�74), each in combination with dexamethasone 20�mg and subcutaneous bortezomib 1�3�mg/m2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6�6, 7�5 and 7�6�months for the tabalumab 100, 300�mg and placebo groups, respectively (tabalumab 100�mg vs. placebo Hazard ratio (HR) [95{\%} confidence interval (CI)]�=�1�13 [0�80–1�59], P�=�0�480; tabalumab 300�mg vs. placebo HR [95{\%} CI]�=�1�03 [0�72–1�45], P�=�0�884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37{\%}), fatigue (37{\%}), diarrhoea (35{\%}) and constipation (32{\%}). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n�=�162) had significantly longer mPFS than those with high BAFF expression (n�=�55), using the 75th percentile cut-off point (mPFS [95{\%} CI]�=�8�3 [7�0–9�3] months vs. 5�8 [3�7–6�6] months; HR [95{\%} CI]�=�1�59 [1�11–2�29], P�=�0�015). Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo. A higher dose of 300�mg tabalumab did not improve efficacy compared to the 100�mg dose. Nonetheless, BAFF appears to have some prognostic value in patients with multiple myeloma.",
keywords = "B-cell activating factor (BAFF), bortezomib, multiple myeloma, tabalumab, treatment",
author = "Raje, {Noopur S.} and Philippe Moreau and Evangelos Terpos and Lotfi Benboubker and Norbert Grząśko and Holstein, {Sarah A} and Albert Oriol and Huang, {Shang Yi} and Meral Beksac and Kazimierz Kuliczkowski and Tai, {Datchen F.} and Wooldridge, {James E.} and Ilaria Conti and Kaiser, {Christopher J.} and Nguyen, {Tuan S.} and Cronier, {Damien M.} and Antonio Palumbo",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/bjh.14483",
language = "English (US)",
volume = "176",
pages = "783--795",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma

AU - Raje, Noopur S.

AU - Moreau, Philippe

AU - Terpos, Evangelos

AU - Benboubker, Lotfi

AU - Grząśko, Norbert

AU - Holstein, Sarah A

AU - Oriol, Albert

AU - Huang, Shang Yi

AU - Beksac, Meral

AU - Kuliczkowski, Kazimierz

AU - Tai, Datchen F.

AU - Wooldridge, James E.

AU - Conti, Ilaria

AU - Kaiser, Christopher J.

AU - Nguyen, Tuan S.

AU - Cronier, Damien M.

AU - Palumbo, Antonio

PY - 2017/3/1

Y1 - 2017/3/1

N2 - In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N�=�72), tabalumab 100�mg (N�=�74), or tabalumab 300�mg (N�=�74), each in combination with dexamethasone 20�mg and subcutaneous bortezomib 1�3�mg/m2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6�6, 7�5 and 7�6�months for the tabalumab 100, 300�mg and placebo groups, respectively (tabalumab 100�mg vs. placebo Hazard ratio (HR) [95% confidence interval (CI)]�=�1�13 [0�80–1�59], P�=�0�480; tabalumab 300�mg vs. placebo HR [95% CI]�=�1�03 [0�72–1�45], P�=�0�884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n�=�162) had significantly longer mPFS than those with high BAFF expression (n�=�55), using the 75th percentile cut-off point (mPFS [95% CI]�=�8�3 [7�0–9�3] months vs. 5�8 [3�7–6�6] months; HR [95% CI]�=�1�59 [1�11–2�29], P�=�0�015). Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo. A higher dose of 300�mg tabalumab did not improve efficacy compared to the 100�mg dose. Nonetheless, BAFF appears to have some prognostic value in patients with multiple myeloma.

AB - In this double-blind, Phase 2 study, 220 patients with relapsed/refractory multiple myeloma were randomly assigned 1:1:1 to receive placebo (N�=�72), tabalumab 100�mg (N�=�74), or tabalumab 300�mg (N�=�74), each in combination with dexamethasone 20�mg and subcutaneous bortezomib 1�3�mg/m2 on a 21-day cycle. No significant intergroup differences were observed among primary (median progression-free survival [mPFS]) or secondary efficacy outcomes. The mPFS was 6�6, 7�5 and 7�6�months for the tabalumab 100, 300�mg and placebo groups, respectively (tabalumab 100�mg vs. placebo Hazard ratio (HR) [95% confidence interval (CI)]�=�1�13 [0�80–1�59], P�=�0�480; tabalumab 300�mg vs. placebo HR [95% CI]�=�1�03 [0�72–1�45], P�=�0�884). The most commonly-reported treatment-emergent adverse events were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Across treatments, patients with low baseline BAFF (also termed TNFSF13B) expression (n�=�162) had significantly longer mPFS than those with high BAFF expression (n�=�55), using the 75th percentile cut-off point (mPFS [95% CI]�=�8�3 [7�0–9�3] months vs. 5�8 [3�7–6�6] months; HR [95% CI]�=�1�59 [1�11–2�29], P�=�0�015). Although generally well tolerated, PFS was not improved during treatment with tabalumab compared to placebo. A higher dose of 300�mg tabalumab did not improve efficacy compared to the 100�mg dose. Nonetheless, BAFF appears to have some prognostic value in patients with multiple myeloma.

KW - B-cell activating factor (BAFF)

KW - bortezomib

KW - multiple myeloma

KW - tabalumab

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85007137226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007137226&partnerID=8YFLogxK

U2 - 10.1111/bjh.14483

DO - 10.1111/bjh.14483

M3 - Article

VL - 176

SP - 783

EP - 795

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -